Loading
A Chinese study of about 14,000 people used to develop and validate Burning Rock's methylation blood test for several cancers.
PREDICT (NCT04383353) is an observational study sponsored by Guangzhou Burning Rock Dx Co., Ltd. It develops and validates a cell-free DNA methylation model, assessing sensitivity, specificity and tissue-of-origin accuracy. The same study has a second registry entry, NCT04817306, sponsored by Shanghai Zhongshan Hospital with Burning Rock.
The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 22 July 2020), with an estimated 14,026 participants, a planned start in 21 July 2020 and primary completion expected in October 2022.
Shares OverC Multi-Cancer Detection Blood Test, Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares OverC Multi-Cancer Detection Blood Test, Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares OverC Multi-Cancer Detection Blood Test, Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares OverC Multi-Cancer Detection Blood Test, Burning Rock Biotech, Multi-cancer early detection (MCED).
Shares OverC Multi-Cancer Detection Blood Test, Burning Rock Biotech, Multi-cancer early detection (MCED).
Shares Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Burning Rock Biotech, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/